DeepMed Research

GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2016-07-28

Last Posted Date: 2020-04-28

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 153

Registration Number: NCT02848651

Locations: 🇺🇸
Franciscan St. Francis Health; Research Services, Indianapolis, Indiana, United States
🇺🇸
Virginia Piper Cancer Inst, Minneapolis, Minnesota, United States
🇺🇸
Levine Cancer Institute-Carolinas Medical Center; Levine Cancer Institute-Carolinas Medical Center, Charlotte, North Carolina, United States

and more 17 locations

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: GDC-0853
Drug: Adalimumab
Drug: Folic Acid
Drug: MTX
Drug: Placebo

First Posted Date: 2016-07-14

Last Posted Date: 2020-06-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 578

Registration Number: NCT02833350

Locations: 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸
Medvin Clinical Research, Covina, California, United States
🇺🇸
TriWest Research Associates, LLC, El Cajon, California, United States

and more 147 locations

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

Phase 1

Completed

Conditions: Neuropathic Diabetic Foot Ulcers

Interventions: Drug: Placebo
Drug: UTTR1147A

First Posted Date: 2016-07-14

Last Posted Date: 2018-11-21

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 72

Registration Number: NCT02833389

Locations: 🇪🇸
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
🇺🇸
Clinical Research Associates Of Central Pa , Llc, Altoona, Pennsylvania, United States
🇪🇸
Universidad Complutense de Madrid, Madrid, Spain

and more 29 locations

A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: RO7105705

First Posted Date: 2016-07-01

Last Posted Date: 2017-07-21

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 74

Registration Number: NCT02820896

Locations: 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Conditions: Multiple Sclerosis

First Posted Date: 2016-06-21

Last Posted Date: 2017-09-07

Lead Sponsor: Genentech, Inc.

Registration Number: NCT02807285

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Steward St. Elizabeth's Medical Center, Boston, Massachusetts, United States
🇺🇸
University Of Texas Health Science Center Houston, Houston, Texas, United States

and more 53 locations

A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-GDC-0810

First Posted Date: 2016-06-16

Last Posted Date: 2016-06-16

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 7

Registration Number: NCT02802670

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Phase 1

Completed

Conditions: Advanced/Metastatic Tumors

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Capecitabine
Drug: Bevacizumab
Drug: Cisplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Etoposide

First Posted Date: 2016-06-09

Last Posted Date: 2024-12-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 518

Registration Number: NCT02794571

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 25 locations

A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)

Phase 1

Completed

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Placebo
Drug: UTTR1147A

First Posted Date: 2016-04-25

Last Posted Date: 2020-10-30

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 70

Registration Number: NCT02749630

Locations: 🇬🇧
Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

Phase 1

Completed

Conditions: Mild Atopic Asthma

Interventions: Drug: Placebo
Drug: BITS7201A

First Posted Date: 2016-04-22

Last Posted Date: 2018-07-03

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 67

Registration Number: NCT02748642

Locations: 🇺🇸
New Orleans Center for Clinical Research; Volunteer Research Group, Knoxville, Tennessee, United States

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: GDC-0310
Drug: Placebo

First Posted Date: 2016-04-19

Last Posted Date: 2020-02-20

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 95

Registration Number: NCT02742779

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy